MedTrace Logo

Role of Aerobic Exercise to Modulate Cardiotoxicity in Long Term Cancer Survivors Exposed to Anthracycline Therapy

NCT04036032 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 47

Last updated 2025-10-14

No results posted yet for this study

Summary

Over 50% of the more than 270,000 childhood cancer survivors in the U.S. have been treated with anthracyclines and thus are at risk of developing cardiotoxicity. The impact of exercise training on LV structure has been extensively studied. Left ventricular hypertrophy and cardiac chamber enlargement with the accompanying ability to generate a large stroke volume are direct results of exercise training. Aerobic exercise therapy offers a non-pharmacological mechanism to modulate multiple gene expression pathways that may promote cardiac remodeling. No prior studies have investigated the efficacy of aerobic exercise in the prevention or treatment of anthracycline-induced cardiotoxicity. We hypothesize that exercise intervention leads to a reverse in adverse cardiac remodeling with improvement of global and regional myocardial function in patients exposed to anthracycline.

Conditions

Interventions

OTHER

Exercise program

Encourage to work out 4 to 5 times a week for 3 months. Patient chooses what exercise they would like to do. At YMCA visit for fitness assessments they provide exercise support

Sponsors & Collaborators

  • Nationwide Children's Hospital

    collaborator OTHER

  • Connecticut Children's Medical Center

    lead OTHER

Principal Investigators

  • Tiffany L Berthod (Ruiz), MSN, RN, CPN, CCRC · Connecticut Children's Medical Center

Eligibility

Min Age
9 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-19
Primary Completion
2025-08-27
Completion
2025-08-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04036032 on ClinicalTrials.gov